Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc....

Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q...

Auris Medical Provides Business Update Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises  AM-301 program progressing towards clinical and regulatory milestones Strategy review ongoing  Hamilton,...